GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

AZD0780

Company
AstraZeneca
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for AZD0780 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07000357

    A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

    Not yet reported AstraZeneca 15100 participants Est. completion 2029-10-26 1452 sites Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT05384262

    A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects

    Not yet reported AstraZeneca 183 participants Est. completion 2024-06-14 3 sites
    Other conditions: Dyslipidemia
    View official trial listing →
  • Completed NCT NCT05787002

    A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.

    Not yet reported AstraZeneca 16 participants Est. completion 2023-05-15 1 site Stand-alone
    Other conditions: Dyslipidemia
    View official trial listing →
  • Completed NCT NCT05817461

    An ADME Study of [14C]AZD0780 in Healthy Male Subjects

    Not yet reported AstraZeneca 8 participants Est. completion 2023-06-06 1 site Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT06173570

    A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia

    Not yet reported AstraZeneca 428 participants Est. completion 2024-09-30 55 sites Stand-alone
    Other conditions: Dyslipidemia
    View official trial listing →
  • Completed NCT NCT06576765

    Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780

    Not yet reported AstraZeneca 16 participants Est. completion 2024-11-08 3 sites Stand-alone
    Other conditions: Hepatic Impairment
    View official trial listing →
  • Completed NCT NCT06592482

    A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780

    Not yet reported AstraZeneca 30 participants Est. completion 2024-12-01 5 sites Stand-alone
    Other conditions: Renal Impairment
    View official trial listing →
  • Completed NCT NCT06671405

    An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions

    Not yet reported AstraZeneca 59 participants Est. completion 2025-02-17 1 site Stand-alone
    Other conditions: Dyslipidaemia
    View official trial listing →
  • Completed NCT NCT06692764

    A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure

    Not yet reported AstraZeneca 202 participants Est. completion 2025-05-02 26 sites Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT06742853

    A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.

    Not yet reported AstraZeneca 81 participants Est. completion 2025-10-29 3 sites Stand-alone
    Other conditions: Dyslipidemia
    View official trial listing →
  • Active, not recruiting NCT NCT06834932

    A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia

    Not yet reported, Not yet reported AstraZeneca 432 participants Est. completion 2027-02-22 42 sites Stand-alone
    Other conditions: Dyslipidaemia
    View official trial listing →
  • Active, not recruiting NCT NCT07000123

    A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

    Not yet reported AstraZeneca 3103 participants Est. completion 2027-01-11 404 sites Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Active, not recruiting NCT NCT07000136

    A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH

    Not yet reported AstraZeneca 473 participants Est. completion 2027-01-04 133 sites Stand-alone
    Other conditions: Heterozygous Familial Hypercholesterolaemia
    View official trial listing →
  • Completed NCT NCT07216131

    A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years

    Not yet reported AstraZeneca 14 participants Est. completion 2025-12-30 1 site Stand-alone
    Other conditions: Healthy Participants
    View official trial listing →
  • Active, not recruiting NCT NCT07218900

    A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia

    Not yet reported AstraZeneca 76 participants Est. completion 2026-09-30 8 sites Stand-alone
    Other conditions: Dyslipidaemia
    View official trial listing →
  • Completed NCT NCT07423598

    A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics With AZD0780 Following Repeated Dose Administration in Healthy Adults With Elevated LDL-C Levels

    Not yet reported AstraZeneca 40 participants Est. completion 2026-06-29 1 site Stand-alone
    Other conditions: Healthy Participants
    View official trial listing →
  • Completed NCT NCT07513571

    A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults

    Not yet reported AstraZeneca 31 participants Est. completion 2026-07-08 1 site
    Other conditions: Healthy Participants
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.